Payment overview · 2025
General Payments
$421.71
21 reported records · 8 companies
Healthcare provider profile · identity verified
William Robert Dailey, MD
Allopathic & Osteopathic Physicians|Family Medicine · OSCEOLA, MO · NPI 1558466458
Verified facts
What the public records show
CMS Open Payments records show William Robert Dailey, MD received $421.71 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.31 | 22.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.71 | 21.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.31 | 17.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.04 | 9.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.58 | 8.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.37 | 7.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.29 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.10 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $421.71 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.31 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $91.71 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.31 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Celecoxib | Celecoxib | 603 | 124 |
| Lisinopril | Lisinopril | 575 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 91 |
| Gabapentin | Gabapentin | 432 | 90 |
| Metformin Hcl | Metformin Hcl | 417 | 78 |
| Omeprazole | Omeprazole | 402 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 384 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 349 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 347 | 84 |
| Famotidine | Famotidine | 304 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 56 |
| Pregabalin | Pregabalin | 262 | 43 |
| Furosemide | Furosemide | 243 | 56 |
| Potassium Chloride | Potassium Chloride | 238 | 49 |
| Mounjaro | Tirzepatide | 228 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 210 | 41 |
| Losartan Potassium | Losartan Potassium | 210 | 47 |
| Tramadol Hcl | Tramadol Hcl | 208 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 44 |
| Prednisone | Prednisone | 172 | 86 |
| Sertraline Hcl | Sertraline Hcl | 162 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 35 |
| Eliquis | Apixaban | 144 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 144 | 23 |
| Finasteride | Finasteride | 135 | 28 |
| Buspirone Hcl | Buspirone Hcl | 131 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 26 |
| Mirtazapine | Mirtazapine | 127 | 25 |
| Trazodone Hcl | Trazodone Hcl | 126 | 23 |
| Azithromycin | Azithromycin | 125 | 105 |
| Montelukast Sodium | Montelukast Sodium | 120 | 16 |
| Allopurinol | Allopurinol | 115 | 20 |
| Bupropion Xl | Bupropion Hcl | 115 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 25 |
| Ozempic | Semaglutide | 103 | 16 |
| Metformin Hcl Er | Metformin Hcl | 102 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 21 |
| Clonazepam | Clonazepam | 95 | 22 |
| Spironolactone | Spironolactone | 95 | 24 |
| Carvedilol | Carvedilol | 94 | 21 |
| Aripiprazole | Aripiprazole | 88 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 74 |
| Donepezil Hcl | Donepezil Hcl | 82 | 12 |
| Alprazolam | Alprazolam | 81 | 23 |
| Mupirocin | Mupirocin | 79 | 66 |
| Trulicity | Dulaglutide | 77 | 18 |
| Fluconazole | Fluconazole | 75 | 34 |
| Meloxicam | Meloxicam | 72 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 63 | 55 |
| Simvastatin | Simvastatin | 61 | 11 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 11 |
| Baclofen | Baclofen | 54 | 11 |
| Colestipol Hcl | Colestipol Hcl | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Diazepam | Diazepam | 51 | 23 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 14 |
| Levofloxacin | Levofloxacin | 46 | 37 |
| Torsemide | Torsemide | 42 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Naproxen | Naproxen | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Roflumilast | Roflumilast | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Ondansetron Odt | Ondansetron | 35 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Nystatin | Nystatin | 34 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 16 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Linzess | Linaclotide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.71 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FANAPT, PREVNAR 20, REXULTI, VRAYLAR, Veozah | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error